|
|
Volumn 4, Issue 3, 2003, Pages 185-187
|
|
Dexanabinol
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DEXANABINOL;
PA 50211;
PLACEBO;
PRS 211007;
TACROLIMUS;
UNCLASSIFIED DRUG;
DRUG DERIVATIVE;
N METHYL DEXTRO ASPARTIC ACID RECEPTOR;
NEW DRUG;
TETRAHYDROCANNABINOL;
TUMOR NECROSIS FACTOR ALPHA;
ANTIOXIDANT ACTIVITY;
ARTICLE;
BRAIN INFARCTION;
BRAIN INJURY;
CLINICAL TRIAL;
COGNITIVE DEFECT;
DOSE RESPONSE;
DRUG BLOOD LEVEL;
DRUG CLEARANCE;
DRUG EFFECT;
DRUG EFFICACY;
DRUG HALF LIFE;
DRUG MARKETING;
DRUG MECHANISM;
DRUG TOLERABILITY;
GLAUCOMA;
HUMAN;
MULTIPLE SCLEROSIS;
NEUROPROTECTION;
NONHUMAN;
PRIORITY JOURNAL;
SPINAL CORD INJURY;
STROKE;
ANIMAL;
DRUG ANTAGONISM;
HEAD INJURY;
REVIEW;
ANIMALS;
CLINICAL TRIALS;
CRANIOCEREBRAL TRAUMA;
DRUGS, INVESTIGATIONAL;
GLAUCOMA;
HUMANS;
RECEPTORS, N-METHYL-D-ASPARTATE;
TETRAHYDROCANNABINOL;
TUMOR NECROSIS FACTOR-ALPHA;
|
|
EID: 0037626714
PISSN: 11745886
EISSN: None
Source Type: Journal
DOI: 10.2165/00126839-200304030-00008 Document Type: Article |
|
Times cited : (4)
|
|
References (9)
|
